Search research articles
Contact Us
Filters
Showing results (71-80 of 93) with videos related to
Page
of 10
Sort By:
Clinical Orthopaedics and Related Research
|
August 1, 1993
Chromosomal assignment of the human gene for bone morphogenetic protein 4
J A Tabas, G V Hahn, R B Cohen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 20, 2015
Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors
E G Chiorean, H I Hurwitz, R B Cohen, et al.
The Journal of Bone and Joint Surgery. American Volume
|
February 1, 1993
The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. A study of forty-four patients
R B Cohen, G V Hahn, J A Tabas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 20, 2014
A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer
A Jimeno, K Shirai, M Choi, et al.
Peptides
|
May 1, 1992
Molecular characterization of angiotensin II type II receptors in rat pheochromocytoma cells
M L Webb, E C Liu, R B Cohen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 1, 1995
Phase I/II study of intermittent all-trans-retinoic acid, alone and in combination with interferon alfa-2a, in patients with epidemic Kaposi's sarcoma
J Bailey, J M Pluda, A Foli, et al.
Cancer Chemotherapy and Pharmacology
|
September 13, 2014
A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors
J Mateo, J Berlin, J S de Bono, et al.
Annals of Surgery
|
February 1, 1985
The use of pathologic features in selecting the extent of surgical resection necessary for breast cancer patients treated by primary radiation therapy
J R Harris, J L Connolly, S J Schnitt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 24, 2008
A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies
M von Mehren, R J Schilder, J D Cheng, et al.
British Journal of Pharmacology
|
September 1, 1994
BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: comparison with losartan and EXP3174
K E Dickinson, R B Cohen, S Skwish, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 93) with videos related to
Sort By:
Page
of 10
Clinical Orthopaedics and Related Research
|
August 1, 1993
Chromosomal assignment of the human gene for bone morphogenetic protein 4
J A Tabas, G V Hahn, R B Cohen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 20, 2015
Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors
E G Chiorean, H I Hurwitz, R B Cohen, et al.
The Journal of Bone and Joint Surgery. American Volume
|
February 1, 1993
The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. A study of forty-four patients
R B Cohen, G V Hahn, J A Tabas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 20, 2014
A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer
A Jimeno, K Shirai, M Choi, et al.
Peptides
|
May 1, 1992
Molecular characterization of angiotensin II type II receptors in rat pheochromocytoma cells
M L Webb, E C Liu, R B Cohen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 1, 1995
Phase I/II study of intermittent all-trans-retinoic acid, alone and in combination with interferon alfa-2a, in patients with epidemic Kaposi's sarcoma
J Bailey, J M Pluda, A Foli, et al.
Cancer Chemotherapy and Pharmacology
|
September 13, 2014
A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors
J Mateo, J Berlin, J S de Bono, et al.
Annals of Surgery
|
February 1, 1985
The use of pathologic features in selecting the extent of surgical resection necessary for breast cancer patients treated by primary radiation therapy
J R Harris, J L Connolly, S J Schnitt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 24, 2008
A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies
M von Mehren, R J Schilder, J D Cheng, et al.
British Journal of Pharmacology
|
September 1, 1994
BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: comparison with losartan and EXP3174
K E Dickinson, R B Cohen, S Skwish, et al.
Page
of 10